# This Page Is Inserted by IFW Operations and is not a part of the Official Record

# BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

	<u> </u>					
					*	
			8 9			
				4		
	•					
					1.4	
	<i>*</i>					
			*			
		•	2			
						<i>w</i>
*	V*	4				
	1 7				1	
						•
÷/						
	•					

.

#### **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classif	ication 6:		(11) International Publication Number:	WO 99/36000
A61F 2/06		A1	(43) International Publication Date:	22 July 1999 (22.07.99)

(21) International Application Number: PCT/US98/27505

(22) International Filing Date: 22 December 1998 (22.12.98)

(30) Priority Data: 09/009,674 20 January 1998 (20.01.98) US

(71) Applicant: HEARTSTENT CORPORATION [US/US]; 651 Campus Drive, St. Paul, MN 55112 (US).

(72) Inventors: TWEDEN, Katherine, S.; 1175 Ashley Lane, Mahtomedi, MN 55115 (US). CONRAD, Timothy, R.; 11068 Branching Horn, Eden Prairie, MN 55347 (US).

(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).

(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


#### Published

With international search report.

Before the expiration of the time limit for amending the

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TRANSMYOCARDIAL IMPLANT WITH SEPTAL PERFUSION



#### (57) Abstract

A transmyocardial implant includes a hollow rigid conduit having a first portion and a second portion. The first portion is sized to be received within a coronary vessel lumen. The first portion has an axial dimension aligned with an axis of the vessel. The second portion is sized to extend from the vessel through a myocardium into a heart chamber. The conduit has open first and second ends on axial ends of respective ones of the first and second portions to define a blood flow pathway within an interior of the conduit between the first and second ends. The first portion has at least one radial opening formed therethrough for blood to flow radially outward of the first portion proximally to the first end.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

П	4.7	A Phone:	700					
ı	AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
l	AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
l	AT	Austria	PR	France	LU	Luxembourg	SN	Senegal
l	AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ı	AZ	Azerbaijan	GB	United Kingdom	MC	Моласо	TD	Chad
l	BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
l	BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
ļ	BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
١	BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
	BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
١	BJ	Benin	IE	l'reland	MN	Mongolia	UA	Ukraine
l	BR	Brazil	π	Israel	MR	Mauritania	UG	Uganda
ı	BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
l	CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
l	CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
l	CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
l	CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
ı	CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
l	CM	Cameroon		Republic of Korea	PL	Poland		
l	CN	China	KR	Republic of Korea	PT	Portugal		
ı	CU	Cuba	KZ	Kazakstan	RO	Romania		
l	CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
l	DE	Germany	Lì	Liechtenstein	SD	Sudan		
l	DK	Denmark	LK	Sri Lanka	SE	Sweden		
L	EE	Estonia	LR	Liberia	SG	Singapore		

WO 99/36000 PCT/US98/27505

#### TRANSMYOCARDIAL IMPLANT WITH SEPTAL PERFUSION

#### BACKGROUND OF THE INVENTION

#### 5 1. Field of the Invention

10

15

20

25

30

This invention pertains to an implant for passing blood flow directly between a chamber of the heart and a coronary vessel. More particularly, this invention pertains to such an implant with an enhance design for providing blood flow to septal perfusing and branching arteries.

#### 2. Description of the Prior Art

Commonly assigned and co-pending U.S. Patent Application Serial No. 08/882,397 filed June 25, 1997, entitled "Method and Apparatus for Performing Coronary Bypass Surgery", and filed in the name of inventors Mark B. Knudson and William L. Giese, teaches an implant for defining a blood flow conduit directly from a chamber of the heart to a lumen of a coronary vessel. An embodiment disclosed in the aforementioned application teaches an L-shaped implant in the form of a rigid conduit having one leg sized to be received within a lumen of a coronary artery and a second leg sized to pass through the myocardium and extend into the left ventricle of the heart. As disclosed in the above-referenced application, the conduit is rigid and remains open for blood flow to pass through the conduit during both systole and diastole. The conduit penetrates into the left ventricle in order to prevent tissue growth and occlusions over an opening of the conduit.

Commonly assigned and co-pending U.S. patent application Serial No. 08/944,313 filed October 6, 1997, entitled "Transmyocardial Implant", and filed in the name of inventors Katherine S. Tweden, Guy P. Vanney and Thomas L. Odland, teaches an implant such as that shown in the aforementioned '397 application with an enhanced fixation structure. The enhanced fixation structure includes a fabric surrounding at least a portion of the conduit to facilitate tissue growth on the exterior of the implant.

Implants such as those shown in the aforementioned applications include a portion to be placed within a coronary vessel and a portion to be placed within the myocardium. When placing a portion of the implant in the coronary vessel, the

WO 99/36000 PCT/US98/27505

vessel is axially incised a length sufficient to insert the implant. When placed within the coronary vessel, the implant discharges flow axially into the vessel. The vessel may have multiple branching vessels. For example, in the case of a coronary artery, numerous septal perfusing arteries may branch off of the coronary artery to provide blood to the septal wall. The septal perfusing arteries branch off of the floor of the coronary artery. In addition to these, additional small arteries may branch off of the sides of the coronary artery. Due to the axial length of the implant within the vessel, the wall of the implant may block blood flow to these branching arteries resulting in localized ischemia.

#### SUMMARY OF THE INVENTION

According to a preferred embodiment of the present invention, a transmyocardial implant is disclosed for establishing a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant includes a hollow rigid conduit having a first portion and a second portion. The first portion is sized to be received within the lumen. The first portion has an axial dimension aligned with an axis of the vessel. The second portion is sized to extend from the vessel through the myocardium into the heart chamber. The conduit has open first and second ends on axial ends of respective ones of the first and second portions to define a blood flow pathway within an interior of the conduit between the first and second ends. The first portion has at least one radial opening formed therethrough for blood to flow radially outward of the first portion proximally to the first end.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 · ·

5

10

15

20

- FIG. 1 is a front, top and left-side perspective view of a first embodiment of an implant according to the present invention;
  - FIG. 2 is a front elevation view of the implant of FIG. 1;
  - FIG. 3 is a bottom plan view of the implant of FIG. 1;
- FIG. 4 is a side elevation view of a second embodiment of an implant according to the present invention;

FIG. 5 is a top plan view of the implant of FIG. 4;

FIG. 6 is a bottom plan view of the implant of FIG. 1; and

FIG. 7 is a view of the implant of FIG. 1 in place following surgical placement.

5

10

15

20

25

30

#### DESCRIPTION OF THE PREFERRED EMBODIMENT

With initial reference to FIG. 1, a conduit 10 is shown in the form of an L-shaped rigid tube. The conduit 10 may be formed of titanium or other rigid biocompatible material such as pyrolytic carbon or may be titanium which is coated with pyrolytic carbon. The material of the conduit 10 is preferably a rigid material in order to withstand contraction forces of the myocardium. By way of example, the tube will have an outside diameter  $D_0$  of about 3 millimeters and an internal diameter  $D_1$  of about 2 millimeters to provide a wall thickness of about .5 millimeters.

The tube 10 has a first portion (or vessel end) 12 which is sized to be received within the lumen of a coronary vessel such as the lumen 80 of a coronary artery 82 illustrated in FIG. 7. The conduit 10 has a second portion (or myocardium end) 14 which extends at a right angle to the axis of portion 12. The second portion 14 is sized to extend from the coronary artery 82 directly through the myocardium 84 and protrude into the left ventricle 86 of a patient's heart. The second portion 14 is sized to have a length sufficient for the portion 14 to protrude into the left ventricle 83.

The vessel end 12 has a first opening 16. The myocardium end 14 has a second opening 18 in communication with an interior 20 of the implant 10. Therefore, blood can freely flow through the implant 10 between the left ventricle 83 and the lumen 80 of the coronary artery 82. Blood flows axially out of opening 16 parallel with the axis of lumen 80.

As discussed more fully in the afore-mentioned commonly assigned and copending U.S. Patent Application Serial No. 08/882,397, the portion 14 may be provided with tissue-growth inducing material (not shown in the present application) to immobilize the implant 10 within the myocardium 84.

The implant 10 includes a radial opening 22 on the vessel portion 12 to permit blood to flow radially outwardly from the vessel portion 12 (relative to the longitudinal axis X - X of vessel portion 12). In the embodiment of FIGS. 1 - 3, the opening 22 is formed by removing the floor of the vessel portion 12 (i.e., that portion of the vessel portion 12 opposing myocardial portion 14). As a result of forming opening 22, septal perfusing arteries may be provided with blood. This is best illustrated in FIG. 7 showing the implant 10 in place. In FIG. 7, the vessel portion 12 is shown residing within a coronary vessel (such as coronary artery 82). The longitudinal axis of the vessel portion is aligned with the axis of the lumen 80. Sutures 24 secure the artery 82 to the vessel portion 12. The proximal portion of the coronary artery is ligated by sutures 85. As shown in FIG. 7, the coronary artery 82 has numerous branching arteries including septal perfusing arteries 86 extending from the floor 88 of the coronary artery 82. With a solid cylindrical vessel portion 12, the arteries 86 within the axial length of the vessel portion 12 will be blocked and deprived of blood. As a result, tissue perfused by these arteries 86 may become ischemic. The opening 22 permits blood to flow radially out of the vessel portion 12 and supply oxygenated blood to these arteries 86.

10

15

20

25

30

FIGS. 4 – 6 illustrate an alternative embodiment implant 10' (all similar elements numbered identically with the addition of an apostrophe). Unlike the embodiment of implant 10 where the opening 22 is formed by removing the base of the vessel portion 12, the implant 10' is provided with a plurality of holes 22' perforating the vessel portion 12' to permit flow radially out of the vessel portion 12'. The holes 22' extend the axially length of the vessel portion 12' and surround the cylindrical wall of the vessel portion 12'. In addition to supplying blood to septal perfusing arteries 86 extending from the floor 88 of the artery 82, the holes 22' supply blood to branching arteries (not shown) which may extend from the sides of the coronary artery 82.

In addition to the open base 22 and holes 22', openings through the vessel portion 12 can be formed in other ways. For example, the vessel portion 12 can be formed of cross-hatched material (similar to stent construction) with areas between the material of the portion 12 defining the openings through the vessel portion 12.

WO 99/36000 PCT/US98/27505

5

10

While not a preferred embodiment, the myocardial portion 14 may be provided with holes to permit radial flow directly into the myocardium 84. This is consistent with well-known transmyocardial revascularization techniques attempting to supply blood to the myocardium directly by forming holes through the myocardium in communication with the left ventricle. However, such a design is not preferred since the myocardium 84 is thrombogenic and such holes may result in thrombus occluding the implant 10, 10°.

Having disclosed the present invention in a preferred embodiment, it will be appreciated that modifications and equivalents may occur to one of ordinary skill in the art having the benefits of the teachings of the present invention. It is intended that such modifications shall be included within the scope of the claims which are appended hereto.

5

10

15

25

30

#### WHAT IS CLAIMED:

A transmyocardial implant for establishing a blood flow path through a
myocardium between a heart chamber and a lumen of a coronary vessel residing
on an exterior of said wall, said implant comprising:


a hollow rigid conduit having a first portion and a second portion; said first portion sized to be received within said lumen, said first portion having an axial dimension aligned with an axis of said vessel;


said second portion sized to extend from said vessel through said myocardium into said chamber;

said conduit having open first and second ends on axial ends of respective ones of said first and second portions to define a blood flow pathway within an interior of said conduit between said first and second ends; and

said first portion having at least one radial opening formed therethrough for blood to flow radially outward of said first portion proximally to said first end.

- A transmyocardial implant according to claim 1 wherein said first portion is
   perforated.
  - 3. A transmyocardial implant according to claim 1 wherein said first portion and second portion are disposed at an angle relative to one another and with said first portion having a base opposing said second portion, said base being substantially open for blood to flow through said base in addition to flowing axially out of said first open end.
  - 4. A transmyocardial implant according to claim 1 wherein the second portion is solid to block radial flow from said second portion.
  - 5. A transmyocardial implant according to claim 1 wherein the first portion is an expandable stent.





### INTERNATIONAL SEARCH REPORT

Inter mal Application No PCT/US 98/27505

		1.10	717 00 307 27 300		
a. classifi IPC 6	CATION OF SUBJECT MATTER A61F2/06	-			
ecording to	International Patent Classification (IPC) or to both national classifica	ation and IPC			
. FIELDS S		on cumbale)			
Minimum doc IPC 6	sumentation searched (classification system followed by classification $A61F$	on symbols)			
Ocumentation	on searched other than minimum documentation to the extent that s	such documents are included	in the fields searched		
Electronic da	ata base consulted during the international search (name of data be	se and, where practical, see	arch terms used)		
C DOCUME	ENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the re	levant passages	Relevant to claim No.		
			1		
A	US 5 429 144 A (WILK) 4 July 199 see the whole document	5	1		
			1		
Α	MASSIMO ET AL: "Myocardial revascularisation by a new metho	d of	1		
	carrying blood directly from the	left			
	ventricular cavity into the coro	nary			
	circulation."				
	JOURNAL OF THORACIC SURGERY,	7 264	^		
	vol. 34, 1 August 1957, pages 25 XP002103311	7-204,			
	see figure 2				
		•	ļ.		
			}		
Fur	ther documents are listed in the continuation of box C.	X Patent family ma	embers are listed in annex.		
° Special c	ategories of cited documents :	"T" later document publis	thed after the international filing date		
"A" docum	nent defining the general state of the art which is not dered to be of particular relevance	cited to understand	not in conflict with the application but the principle or theory underlying the		
	dered to be of particular relevance document but published on or after the international	invention "X" document of particular	ar relevance; the claimed invention		
filing		cannot be considere involve an inventive	ed novel of cannot be considered to		
which	ient which in a which is the publication date of another on or other special reason (as specified)	"Y" document of particular	ar relevance; the claimed invention and to involve an inventive step when the		
"O" docum	nent referring to an oral disclosure, use, exhibition or	document is combit	ned with one or more other such docu- nation being obvious to a person skilled		
"P" docum	r means nent published prior to the international filing date but than the priority date claimed	in the art.  *&* document member of the same patent family			
	e actual completion of the international search		ne international search report		
	20 May 1999	01/06/19	999		
Name and	i mailing address of the ISA	Authorized officer			
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk				
	Tel. (-31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Smith, (	C		

# INTERNATIONAL SEARCH REPORT

International Application No

	adormation on patent family members			PCT/US	98/27505
Patent document cited in search repor		Publication date		atent family member(s)	Publication date
US 5429144	Α	04-07-1995	US US	5409019 A 5287861 A	25-04-1995 22-02-1995

THIS PAGE BLANK (USPTO)